Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 38.7%

Posted by Francis Steltz on Jul 16th, 2026

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 16,698 shares, a decrease of 38.7% from the June 15th total of 27,250 shares. Based on an average trading volume of 39,560 shares, the short-interest ratio is currently 0.4 days. Currently, 1.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BOLT. Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $34.67.

Get Our Latest Analysis on Bolt Biotherapeutics

Bolt Biotherapeutics Stock Up 4.0%

Shares of NASDAQ BOLT opened at $4.21 on Thursday. The company has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $4.89. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. Bolt Biotherapeutics has a 1 year low of $3.75 and a 1 year high of $7.20. The firm has a market cap of $8.08 million, a PE ratio of -0.26 and a beta of 1.16.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million. On average, research analysts forecast that Bolt Biotherapeutics will post -11.1 EPS for the current year.

Institutional Trading of Bolt Biotherapeutics

Several institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC raised its position in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at about $85,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics in the third quarter valued at about $89,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $112,000. Finally, T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter worth about $208,000. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.